Weed (BUDZ) Net Income towards Common Stockholders (2010 - 2026)
Weed's (BUDZ) quarterly Net Income towards Common Stockholders came in at -$175256.0 in Q1 2026, up 60.21% year-on-year from -$109391.3 in Q1 2025, and up 91.74% quarter-over-quarter from -$2.1 million in Q4 2025.
Weed (BUDZ) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Weed's Net Income towards Common Stockholders history runs 13 years deep, the most recent figure standing at -$175256.0 for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 60.21% year-over-year to -$175256.0 in Q1 2026; TTM through Mar 2026 was -$2.5 million, a 217.63% decrease from a year earlier, with the FY2025 full-year figure at -$2.7 million, down 437.35% from the prior year.
- Net Income towards Common Stockholders grew to -$175256.0 in Q1 2026 per BUDZ's latest filing, from -$2.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $734248.0 in Q3 2023 and bottomed at -$4.0 million in Q2 2023.
- The 5-year median for Net Income towards Common Stockholders is -$192312.0 (2022), against an average of -$989428.2.
- Across the five-year window, Net Income towards Common Stockholders sank 1543.81% in 2022 and soared 124.53% in 2023, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$192312.0 in 2022, then slumped by 105.07% to -$394368.0 in 2023, then soared by 66.22% to -$133224.0 in 2024, then slumped by 1493.05% to -$2.1 million in 2025, then surged by 91.74% to -$175256.0 in 2026.
- Per Business Quant, the three latest BUDZ Net Income towards Common Stockholders figures stand at -$175256.0 (Q1 2026), -$2.1 million (Q4 2025), and -$73946.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Weed | 3.10 Mn | 3.10 Mn | - | -175,256.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -175,256.00 |
| Dec 31, 2025 | -2.12 Mn |
| Sep 30, 2025 | -73,946.00 |
| Jun 30, 2025 | -107,616.00 |
| Mar 31, 2025 | -440,455.00 |
| Dec 31, 2024 | -133,224.00 |
| Sep 30, 2024 | -95,887.00 |
| Jun 30, 2024 | -110,953.00 |
| Mar 31, 2024 | -170,652.00 |
| Dec 31, 2023 | -394,368.00 |
| Sep 30, 2023 | 734,248.00 |
| Jun 30, 2023 | -3.99 Mn |
| Mar 31, 2023 | -197,014.00 |
| Dec 31, 2022 | -192,312.00 |
| Sep 30, 2022 | -2.99 Mn |
| Jun 30, 2022 | -3.08 Mn |
| Mar 31, 2022 | -3.28 Mn |
| Dec 31, 2021 | -467,504.00 |
| Sep 30, 2021 | -182,101.00 |
| Jun 30, 2021 | -1.22 Mn |